Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula (I)



(I)

wherein:
one of Z_1, Z_2, Z_3, Z_4 and Z_5 is N, one is CR^{1a} and the remainder are CH, or
one or two of Z_1, Z_2, Z_3, Z_4 and Z_5 are independently CR^{1a} and the remainder are CH;

R^1 and R^{1a} are independently hydrogen; hydroxy; (C_{1-6})alkoxy unsubstituted or substituted by (C_{1-6})alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups, $CONH_2$, hydroxy, (C_{1-6})alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6})alkylsulphonyloxy; (C_{1-6})alkoxy-substituted(C_{1-6})alkyl; halogen; (C_{1-6})alkyl; (C_{1-6})alkylthio; trifluoromethyl; trifluoromethoxy; nitro; cyano; azido; acyl; acyloxy; acylthio; (C_{1-6})alkylsulphonyl; (C_{1-6})alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups; provided that when Z_1, Z_2, Z_3, Z_4 and Z_5 are CR^{1a} or CH, then R^1 is not hydrogen;

each R^2 is independently hydrogen, OH, NH_2, substituted or unsubstituted (C_{1-6})alkyl, or substituted or unsubstituted (C_{1-6})alkoxy;

R^3 is H, or substituted or unsubstituted (C_{1-6})alkyl;

R^4 is a group -U-R^5 where

U is selected from CH_2, C=O, and SO_2 and

R^5 is a substituted or unsubstituted aryl group, or a substituted or unsubstituted bicyclic carbocyclic or heterocyclic ring system (A):



(A)

containing up to four heteroatoms in each ring in which

ring (a) is aromatic and ring (b) is non-aromatic;

X^1 is C;

X^2 is N or CR^6;

X^3 and X^5 are C;

Y^1 is a 0 to 3 atom linker group, each atom of which is independently selected from N and CR^6;

Y^2 is a 2 to 6 atom linker group, each atom of Y^2 being independently selected from N, NR^8, O, S(O)x, CO, CR^6 and CR^6R^7;

each of R^6 and R^7 is independently selected from: hydrogen; (C_{1-4})alkylthio; halo; carboxy(C_{1-4})alkyl; halo(C_{1-4})alkoxy; halo(C_{1-4})alkyl; (C_{1-4})alkyl; ~~(C_{2-4})alkenyl;~~ (C_{1-4})alkoxycarbonyl; formyl; (C_{1-4})alkylcarbonyl; (C_{2-4})alkenyloxycarbonyl; (C_{2-4})alkenylcarbonyl; (C_{1-4})alkylcarbonyloxy; (C_{1-4})alkoxycarbonyl(C_{1-4})alkyl; hydroxy; hydroxy(C_{1-4})alkyl; mercapto(C_{1-4})alkyl; (C_{1-4})alkoxy; nitro; cyano; carboxy; amino ~~or~~ wherein the amino group is optionally substituted by (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl, (C_{1-4})alkyl or (C_{2-4})alkenyl and optionally further substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; ~~or~~ (C_{2-6})alkenyl; (C_{1-4})alkylsulphonyl; (C_{2-4})alkenylsulphonyl; ~~or~~ aminosulphonyl wherein the amino group is optionally mono- or di-substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; aryl; aryl(C_{1-4})alkyl; **and** aryl(C_{1-4})alkoxy;

each R^8 is independently hydrogen; trifluoromethyl; (C_{1-4})alkyl unsubstituted or substituted by hydroxy, (C_{1-6})alkoxy, (C_{1-6})alkylthio, halo or trifluoromethyl; (C_{2-4})alkenyl; aryl; aryl (C_{1-4})alkyl; arylcarbonyl; heteroarylcarbonyl; (C_{1-4})alkoxycarbonyl; (C_{1-4})alkylcarbonyl; formyl; (C_{1-6})alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C_{1-}

$_4$)alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl, (C_{1-4})alkyl or (C_{2-4})alkenyl and optionally further substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; and
x is 0, 1, or 2; or
a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 wherein Z_5 is CH or N, Z_3 is CH or CF and Z_1, Z_2 and Z_4 are each CH, or Z_1 is N, Z_3 is CH or CF and Z_2, Z_4 and Z_5 are each CH.

3. (Original) A compound according to claim 1 wherein R^1 is methoxy and R^{1a} is H or when Z_3 is CR^{1a} it may be C-F.

4. (Original) A compound according to claim 1 wherein in the heterocyclic ring (A) Y^2 has 3-5 atoms including NR^8, O or S bonded to X^5 and NHCO bonded via N to X^3, or O or NH bonded to X^3.

5. (Currently Amended) A compound according to claim 1 wherein R^6 and R^7 are independently hydrogen; hydroxy; halo; or (C_{1-4})alkyl **unsubstituted or substituted** ~~substituted or unsubstituted~~ by hydroxy, (C_{1-6})alkoxy, (C_{1-6})alkylthio, halo or trifluoromethyl; (C_{2-4})alkenyl; **or** (C_{1-4})alkoxycarbonyl.

6. (Original) A compound according to claim 1 wherein R^5 is selected from 1H-Indol-2-yl, quinolin-8-ol-2-yl, 3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-yl, 4H-benzo[1,4]oxazin-3-one-6-yl, 4-Fluoro-1H-benzoimidazol-2-yl, 3,6-dimethyl-3H-benzooxazol-2-one, 4H-benzo[1,4]thiazin-3-one-6-yl, 3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-yl, 4-Oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepine-7-yl, 7-Chloro-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-yl, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine-6-yl, and 4H-pyrido[3,2-b][1,4]oxazin-3-one-6-yl.

7. (Original) A compound according to claim 1 which is:
3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-sulfonic acid {3-[(R)-5-(6-methoxy-quinolin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide;
4-Oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepine-7-sulfonic acid {3-[(R)-5-(6-methoxy-quinolin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide;
3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-sulfonic acid {3-[(R)-5-(6-methoxy-quinolin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide;
7-Chloro-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-sulfonic acid {3-[(R)-5-(6-

methoxy-quinolin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide;
3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-sulfonic acid {3-[(R)-5-(8-fluoro-6-methoxy-quinolin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide;
3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-sulfonic acid {3-[(R)-5-(6-methoxy-[1,5]naphthyridin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide;
3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-sulfonic acid {3-[(S)-5-(6-methoxy-[1,5]naphthyridin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide;
3-Oxo-3,4-dihydro-2H-benzo[1,4]oxazine-6-sulfonic acid {3-[(R)-5-(6-methoxy-[1,5]naphthyridin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide;
3-Oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]thiazine-6-carboxylic acid {3-[(R)-5-(6-methoxy-quinolin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide;
(R)-3-{3-[(1H-Indol-2-ylmethyl)-methyl-amino]-propyl}-5-(6-methoxy-quinolin-4-yl)-oxazolidin-2-one;
(R)-3-{3-[(Benzo[1,2,5]thiadiazole-5-ylmethyl)-amino]-propyl}-5-(6-methoxy-quinolin-4-yl)-oxazolidin-2-one;
(R)-3-{3-[(1H-Indol-2-ylmethyl)-amino]-propyl}-5-(6-methoxy-quinolin-4-yl)-oxazolidin-2-one;
(R)-3-{3-[(8-Hydroxy-quinolin-2-ylmethyl)-methyl-amino]-propyl}-5-(6-methoxy-quinolin-4-yl)-oxazolidin-2-one;
(R)-3-{3-[(4-Fluoro-1H-benzoimidazol-2-ylmethyl)-amino]-propyl}-5-(6-methoxy-quinolin-4-yl)-oxazolidin-2-one;
6-({3-[(R)-5-(6-Methoxy-quinolin-4-yl)-2-oxo-oxazolidin-3-yl]-propylamino}-methyl-4H-benzo[1,4]oxazin-3-one;
(R)-3-{3-[(8-Hydroxy-quinolin-2-ylmethyl)-amino]-propyl}-5-(6-methoxy-quinolin-4-yl)-oxazolidin-2-one;
(6-({3-[(R)-5-(6-Methoxy-quinolin-4-yl)-2-oxo-oxazolidin-3-yl]-propylamino}-methyl-4H-benzo[1,4]thiazin-3-one;
6-({3-[(R)-5-(6-Methoxy-quinolin-4-yl)-2-oxo-oxazolidin-3-yl]-propylamino}-methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({3-[(R)-5-(8-Fluoro-6-methoxy-quinolin-4-yl)-2-oxo-oxazolidin-3-yl]-propylamino}-methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
3-Oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-sulfonic acid{3-[(R)-5-(6-methoxy-[1,5]naphthyridin-4-yl)-2-oxo-oxazolidin-3-yl]-2,2-dimethyl-propyl}-amide;
2,3-Dihydro-benzo[1,4]dioxine-6-sulfonic acid {3-[5-(6-methoxy-[1,5]naphthyridin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide;
6-({3-[5-(6-Methoxy-[1,5]naphthyridin-4-yl)-2-oxo-oxazolidin-3-yl]-propylamino}-methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({3-[5-(6-Methoxy-[1,5]naphthyridin-4-yl)-2-oxo-oxazolidin-3-yl]-propylamino}-methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;
3-Oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-sulfonic acid {(R)-2-hydroxy-3-[(R)-5-(6-methoxy-[1,5]naphthyridin-4-yl)-2-oxo-oxazolidin-3-yl]-propyl}-amide;
6-({(S)-2-Hydroxy-3-[(R)-5-(6-methoxy-[1,5]naphthyridin-4-yl)-2-oxo-oxazolidin-3-yl]-propylamino}-methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;
3-Oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-sulfonic acid {(S)-2-hydroxy-3-[(R)-5-(6-methoxy-[1,5]naphthyridin-4-yl}-2-oxo-oxazolidin-3-yl]-propyl}-amide; or
6-({(R)-2-Hydroxy-3-[(R)-5-(6-methoxy-[1,5]naphthyridin-4-yl)-2-oxo-oxazolidin-3-yl]-propylamino}-methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one; or
a pharmaceutically acceptable salt thereof.

8. (Original) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

9. (Original) A method of treating bacterial infections in mammals which comprises the administration to a mammal in need thereof an effective amount of a compound according to claim 1.

10. (New) A pharmaceutical composition comprising a compound according to claim 7 and a pharmaceutically acceptable carrier.

11. (New) A method of treating bacterial infections in mammals which comprises the administration to a mammal in need thereof an effective amount of a compound according to claim 7.